ClinicalTrials.gg
Active, not recruitingNCT04128995ST2OMPUpdated Mar 24, 2026

Surgical or Medical Treatment

A Phase 4 interventional study of Advanced Medical Therapy and Bariatric Surgery and Advanced Medical Therapy in Diabetes Mellitus, Type 2, Pediatric Obesity and Bariatric Surgery Candidate, sponsored by Children's Hospital Medical Center, Cincinnati. Active, not recruiting at 3 sites in United States. Open to participants aged 13 Years to 19 Years. Per ClinicalTrials.gov, last updated 2026-03-24.

Sponsored by Children's Hospital Medical Center, Cincinnati · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
88
Allocation
Non-randomized
Ages
13 Years to 19 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States — 345 open to participants now, 479 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,505th of 2,961
88 · median 90
Started
2019
with 132 others
Phase 4
300 of 3,308
19 open now
Primary completion
2026-12
later than 144 of 477 live
Registered
2,284th of 3,308
by date

Among the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,505th largest by enrollment of the 2,961 interventional ones that give a count, is one of 133 that started in 2019, is one of 300 in phase 4, reaches primary completion later than 144 of the 477 other live ones, and was the 2,284th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

345 of the 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

340 more — sign in →

All 345 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 13 Years to 19 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,308 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This study will test the hypothesis that metabolic bariatric surgery will be more effective at providing durable glycemic control and reduce co-morbidities than intensive medical therapy in youth with type 2 diabetes.

Read the detailed description

Youth-onset type 2 diabetes (T2D) leads to early dependence on exogenous insulin and progression of T2D co-morbidities, including dyslipidemia, hypertension, non-alcoholic fatty liver disease and diabetic kidney disease. The pathophysiology of T2D in youth differs considerably from adults and current treatment approaches are in-adequate for youth. Thus, exploration of innovative approaches to reduce co-morbidities is critical. Metabolic bariatric surgery (MBS) significantly improves multiple outcomes in adults with T2D. Initial small, uncontrolled studies of Roux-en-Y gastric bypass also suggest beneficial effects in youth with T2D, but definitive studies and understanding of mechanisms in youth-onset T2D are lacking, especially with the now more common form of MBS, vertical sleeve gastrectomy (VSG).

We will test the hypothesis that VSG will be more effective in reducing glycemia and comorbidities than the best currently available medical treatment: advanced medical therapy (AMT), via pancreatic, enterohepatic and/or metabolic changes. To test this hypothesis, 90 adolescents with T2D will be studied to compare the effects of VSG vs. AMT on glycemic control and T2D-associated comorbidities, as well as underlying mechanisms.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Pediatric Obesity
  • Bariatric Surgery Candidate
04

Who can participate

Ages eligible
13 Years to 19 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion Criteria for the medical or surgical type 2 diabetes groups

  • Age 13-19.9 years of age at time of signing the consent
  • Type 2 diabetes by the American Diabetes Association criteria
  • Negative diabetes-associated antibodies

Exclusion Criteria for the medical or surgical type 2 diabetes groups Known type 1 diabetes, maturity onset diabetes of the young (MODY), or secondary diabetes

  • Any chronic oral use within 60 days of enrollment
  • Current pancreatotoxic drugs
  • Chronic kidney or liver disease (except NAFLD or DKD)
  • Pregnancy, breast-feeding or intension of becoming pregnant
  • Prior bariatric surgery
  • History of
  • Current participation in another clinical trial that may affect study outcomes
  • Other conditions, that in the determination of the study investigator, may interfere with study participation

Inclusion criteria

  • Age 13-19.9 years of age at time of signing the consent
  • Clinical indication to receive bariatric surgery

Exclusion criteria

Exclusion Criteria for the obese control group

  • Known diabetes
  • Any chronic oral use within 60 days of enrollment
  • Current pancreatotoxic drugs
  • Chronic kidney or liver disease (except NAFLD or DKD)
  • Pregnancy, breast-feeding or intension of becoming pregnant
  • Prior bariatric surgery
  • History of
  • Current participation in another clinical trial that may affect study outcomes
  • Other conditions, that in the determination of the study investigator, may interfere with study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (actual)

Study arms

  • Active comparator
    Medical Therapy and Bariatric Surgery in Youth with Type 2 Diabetes

    Youth with type 2 diabetes undergoing bariatric surgery, n=45

    Procedure: Advanced Medical Therapy and Bariatric Surgery

  • Active comparator
    Medical Therapy in Youth with Type 2 Diabetesin Youth with Type 2 Diabetes

    Youth with type 2 diabetes receiving medical management, n=45

    Drug: Advanced Medical Therapy

  • Active comparator
    Bariatric Surgery in Youth with Obesity

    Youth with no obesity undergoing bariatric surgery, n=10

    Procedure: Bariatric Surgery

Interventions

  • ProcedureAdvanced Medical Therapy and Bariatric Surgery

    Vertical Sleeve Gastrectomy and Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes

  • DrugAdvanced Medical Therapy

    Advanced Medical Therapy that could include metformin, GLP-1 agonist, SGLT-2 inhibitor, or basal insulin for youth with type 2 diabetes

  • ProcedureBariatric Surgery

    Vertical Sleeve Gastrectomy for youth without type 2 diabetes

    Also known as: Vertical Sleeve Gastrectomy

06

What researchers measure

Primary outcomes

  1. Glycemic Control

    Hemoglobin A1c of \<6.5%

    Time frame: At one year

Secondary outcomes

  1. Glycemic Control

    Hemoglobin A1c \<6.5% at 2 years

    Time frame: At two years

  2. Glycemic Variability

    Time In Range by Continuous Glucose Monitoring

    Time frame: At one year

  3. Beta Cell Function

    Oral disposition index= Insulin secretion \[insulinogenic index\] \* insulin sensitivity \[1/fasting insulin\]

    Time frame: at 1 and 2 years

  4. Alpha cell function

    Glucagon area under the curve from mixed meal tolerance testing

    Time frame: at 1 and 2 years

  5. Incretin Response

    GLP-1 area under the curve from mixed meal tolerance testing

    Time frame: at 1 and 2 years

  6. Fatty Liver Disease

    Hepatic Fat (\<5% )by Magnetic Resonance imaging

    Time frame: at 1 and 2 years

  7. Dyslipidemia

    LDL \<130mg/dL

    Time frame: at 1 and 2 years

  8. Hypertension

    Blood pressure \<130/80 mmHg

    Time frame: at 1 and 2 years

  9. Diabetic Kidney Disease

    Urinary albumin excretion \<30μg/mg

    Time frame: At 1 and 2 years

07

Study locations

3 sites
08

References and documents

Publications

  • Shah AS, Helmrath MA, Inge TH, Xanthakos SA, Kelsey MM, Jenkins T, Trout AT, Browne L, Nadeau KJ. Study protocol: a prospective controlled clinical trial to assess surgical or medical treatment for paediatric type 2 diabetes (ST2OMP). BMJ Open. 2021 Aug 13;11(8):e047766. doi: 10.1136/bmjopen-2020-047766. PubMed 34389568 ↗

Individual participant data

Plan to share: No — The PI's will also report a of summary results information (including adverse events) after completion of the study. All data from the study including any negative findings will be published in peer reviewed manuscripts.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2019 (actual). Primary completion is estimated for Dec 2026, 84 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 84 months is above that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2019
First posted
Oct 16, 2019
StartActual
Dec 15, 2019
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Mar 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04128995
Collaborators
Children's Hospital Colorado
Responsible party
Amy Shah (Professor, Department of Pediatrics, Children's Hospital Medical Center, Cincinnati) — Principal investigator
First posted
Oct 16, 2019
Start date
Dec 15, 2019
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 24, 2026

Study contacts

Amy S Shah, MD MS
principal investigator · Cincinnati Childrens Hospital Medical Center
Kristen J Nadeau, MD MS
principal investigator · Children's Hospital Colorado
Michael A Helmrath, MD MS
principal investigator · Children's Hospital Medical Center, Cincinnati
Thomas H Inge, MD PhD
principal investigator · Ann & Robert H Lurie Children's Hospital of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion